Roche Notches Big IO Win With Tecentriq/Avastin Combo In First-Line HCC

 
• By Joseph Haas

Following quickly on a Bristol trial failure with Opdivo in first-line HCC, Roche’s PD-L1 inhibitor looks poised to be the first immunotherapy approved in the setting, with plans for US, EU and China filings.

SC1910_Liver-tissue-samples_1052884202_1200.jpg
Roche hopes to offer the first OS improvement in more than a decade in HCC

More from Clinical Trials

More from R&D